Table 1 Characteristics of the patients (N = 156)

Age (years)

 Median

60 (27–76)

 ≤ 40

6 (3.8%)

 41–65

114 (73.1%)

 ≥ 66

36 (23.1%)

Sex

 Male

114 (73.1%)

 Female

42 (26.9%)

Operative hospital

 Our hospital

93 (59.6%)

 Another hospital

63 (40.4%)

Operative approach

 Proximal subtotal gastrectomy

24 (15.4%)

 Distal subtotal gastrectomy

69 (44.2%)

 Total gastrectomy

53 (34.0%)

 Gastrectomy combined with resection of other organs

10 (6.4%)

Location of primary tumor

 Upper 1/3

39 (25%)

 Middle 1/3

33 (21.2%)

 Lower 1/3

69 (44.2)

 Total stomach

15 (9.6%)

Pathologic types

 Well to moderately differentiated adenocarcinoma

52 (33.3%)

 Poorly differentiated adenocarcinoma

82 (52.6%)

 Mucinous adenocarcinoma

9 (5.8%)

 Signet ring cell adenocarcinoma

12 (7.7%)

 Neuroendocrine degeneration

1 (0.6%)

Lauren's classification

 Intestinal type

63 (40.4%)

 Diffuse type

86 (55.1%)

 Mixed unclassified

7 (4.5%)

No. of dissected LNs

 Median

19 (5–56)

 < 15

52 (33.3%)

 ≥ 15

104 (66.7%)

No. of positive LNs

 Median

5 (0–47)

 LNR = 0

24 (15.3%)

 0 < LNR < 0.3

58 (37.2%)

 0.3 ≤ LNR < 0.7

53 (34.0%)

 0.7 ≤ LNR

21 (13.5%)

Pathologic T stage

 T1

8 (5.1%)

 T2

19 (12.2%)

 T3

73 (46.8%)

 T4a

31 (19.9%)

 T4b

25 (16.0%)

Pathologic N stage

 N0

23 (14.7%)

 N1

30 (19.2%)

 N2

37 (23.7%)

 N3a

53 (34.0%)

 N3b

13 (8.3%)

Stage

 IB

3 (1.9%)

 IIA

26 (16.7%)

 IIB

23 (14.7%)

 IIIA

37 (23.7%)

 IIIB

40 (25.6%)

 IIIC

27 (17.3%)

Lymphovascular invasion (LVI)

 Negative

74 (47.4%)

 Positive

82 (52.6%)

Perineural invasion (PNI)

 Negative

83 (53.2%)

 Positive

73 (46.8%)

Concurrent chemotherapy regimen

 Capecitabine

88 (56.4%)

 S-1

22 (14.1%)

 Others

46 (29.5%)

Adjuvant chemotherapy regimen

 XELOX

76 (48.7%)

 SOX

27 (17.3%)

 FLOFOX

13 (8.3%)

 EOF

14 (9.0%)

 FLOT

4 (2.6%)

 Others

22 (14.1%)